27 results about "Polycystic ovary" patented technology

The application belongs to the technical field of biomedicine, and particularly relates to a miRNA marker for diagnosing polycystic ovary syndrome and application thereof. The miRNA marker comprises one or a combination of hsa-miR-185-5p and hsa-miR-4433b-3p. The application first uses a plurality of extracellular vesicle (EVs) miRNAs such as hsa-miR-185-5p for diagnosing polycystic ovary syndrome patients, and it is found through verification in real clinical samples collected in the application that the plurality of extracellular vesicle (EVs) miRNAs such as hsa-miR-185-5p have good diagnostic efficiency for diagnosing polycystic ovary syndrome, and have high accuracy, sensitivity and specificity, and can be used for effective diagnosis of polycystic ovary syndrome. The application provides a brand-new thought and strategy for research and development of polycystic ovary syndrome related diagnostic products, and has a wide application prospect and important transformation significance in the technical field of polycystic ovary syndrome diagnosis.

1. The name of the design product: medical detection chip. 2. The use of the design product: the design product is used for non-invasive early screening of polycystic ovary syndrome. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: design 1 perspective view 1. 5. Design 1 is designated as the basic design.

This application relates to the field of medical data processing technology and discloses a method and system for screening infertile patients with polycystic ovary syndrome (PCOS). The method includes: acquiring data on the number of antral follicles, anti-Müllerian hormone (AMH) concentration, and ovarian volume from multiple patient monitoring cycles; performing feature extraction and normalization to obtain a set of normalized feature vectors; determining the synchronous relationship between the number of antral follicles and ovarian volume based on the vector set, and identifying signs of asynchronous changes; combining hormone concentrations for joint grouping to obtain the distribution of abnormal indicator clusters and identifying ovarian function stage markers; performing sequence matching based on the stage markers of continuous cycles and historical medical records to generate an ovarian function progression trajectory curve; extracting inflection point features from the curve and performing causal association rule mining to construct a logical chain between abnormal indicators and clinical outcomes; and determining conditions layer by layer according to the logical chain to output the final screening results. This application improves the accuracy of screening infertile patients with PCOS.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, preparation, preparation method, and application for treating polycystic ovary syndrome (PCOS). The traditional Chinese medicine composition for treating PCOS comprises the following raw materials in parts by weight: 10-15 parts of Cuscuta chinensis, 10-15 parts of Lycium barbarum, 10-20 parts of Taxillus chinensis, 10-15 parts of Angelica sinensis, 10-15 parts of Achyranthes bidentata, 10-15 parts of Ligusticum chuanxiong, 10-15 parts of Alisma plantago-aquatica, 10-15 parts of Nelumbo nucifera leaf, 10-15 parts of Gynostemma pentaphyllum, 10-20 parts of Salvia miltiorrhiza, 5-10 parts of Euonymus alatus, 5-10 parts of Coptis chinensis, and 5-10 parts of Glycyrrhiza uralensis. Its core treatment principle is to tonify the kidney and spleen, promote blood circulation, and resolve phlegm, and it is used to treat PCOS.

This invention relates to the field of biomedical technology and discloses a biomarker for diagnosing polycystic ovary syndrome (PCOS) and its application. The diagnostic biomarker is circSPECC1(4), which is formed by reverse splicing and circularization of the fourth exon of the SPECCC1 gene. It has a length of 1580 nt and possesses a closed circular RNA structure. circSPECC1(4) is specifically highly expressed in ovarian granulosa cells of PCOS patients, and there is no significant difference in the mRNA expression level of its parent gene SPECCC1. circSPECC1(4) possesses RNase R nuclease resistance stability and is mainly located in the cytoplasm. Knocking down the expression of circSPECC1(4) can significantly promote apoptosis of ovarian granulosa cells and arrest the ovarian granulosa cell cycle at the G0 / G1 phase. This invention clearly demonstrates that circSPECC1(4) can serve as a specific diagnostic biomarker for PCOS, fully verifying the structural characteristics, expression specificity, and pathological regulatory function of this circular RNA, filling the gap in the existing field of PCOS diagnosis which lacks highly specific and stable molecular diagnostic targets.

The application provides a traditional Chinese medicine compound for treating polycystic ovary syndrome insulin resistance, and relates to the technical field of traditional Chinese medicine preparation. In the traditional Chinese medicine compound, gentiana scabra, and sophora flavescens are used as monarch drugs, scrophularia ningpoensis, sophora flavescens, smilax glabra, and radix rehmanniae are used as ministerial drugs, and then, humulus scandens, plantago, angelica sinensis, taraxacum, lycopus virginicus, luffa, chihkiu, and curcuma zedoary are used as auxiliary drugs. The whole prescription is used for clearing heat and drying dampness, purging fire and nourishing yin, and promoting dampness and dredging collaterals, and is suitable for treating polycystic ovary syndrome insulin resistance of the liver meridian damp-heat type.

The application discloses a traditional Chinese medicine composition for treating menstrual disorder and acne symptoms and a preparation method thereof, mainly aims at kidney deficiency and damp-heat type polycystic ovary syndrome (PCOS) patients, and comprises the following raw materials in parts by weight: 9-12g of angelica sinensis, 12g of prepared rehmannia, 12g of fried white peony root, 9-12g of chuanxiong rhizome, 9g of fried pinellia, 9g of cyperus rotundus, 9g of loquat leaf, 9g of forsythia, and 15g of caulis microcosmi. The traditional Chinese medicine composition is developed based on the diagnosis and treatment theory of traditional Chinese medicine, has scientific and reasonable formula, simple preparation process, safety, stability and effectiveness, and has the effect of obviously improving the menstrual disorder and acne symptoms of the kidney deficiency and damp-heat type polycystic ovary syndrome patients.

1. The name of the design product: intelligent light regulation glasses (adjustable angle). 2. The use of the design product: for treating polycystic ovary infertility by using AI algorithm. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

This invention relates to a pharmaceutical composition for treating gynecological diseases, its preparation method, and its application, belonging to the field of gynecological disease treatment technology. The pharmaceutical composition comprises the following raw materials: *Sedum aizoon*, *Trichosanthes kirilowii* seeds, and *Xanthoceras sorbifolium* leaves; the weight ratio of *Sedum aizoon*, *Trichosanthes kirilowii* seeds, and *Xanthoceras sorbifolium* leaves is (10-20):(6-9):(3-7). This invention mainly utilizes a suitable ratio of *Sedum aizoon*, *Trichosanthes kirilowii* seeds, and *Xanthoceras sorbifolium* leaves for synergistic effect, significantly improving the therapeutic efficacy of the pharmaceutical composition for gynecological diseases such as polycystic ovary syndrome, providing a new approach for treating gynecological diseases, and has broad clinical application prospects.

The application provides use of an inhibitor targeting IL-11 or an IL-11 receptor in preparation of a drug for delaying ovarian aging, and first discloses and proves that an inflammatory factor interleukin-11 (IL-11) is a core target point for driving ovarian aging and an increase in ovarian matrix stiffness and fibrosis under pathological conditions such as chemotherapy damage and polycystic ovary syndrome, and the interleukin-11 promotes excessive secretion of collagen by activating an IL-11RA / ERK signal axis in ovarian fibroblasts. Based on this, the application provides a new use of an inhibitor (such as specific siRNA and a neutralizing antibody) targeting IL-11 or the receptor thereof in preparation of a related therapeutic drug. In particular, a liposome nanoparticle loaded with IL-11 siRNA can effectively reduce ovarian stiffness, reduce fibrosis, significantly improve follicle reserve, hormone level and fertility, and successfully reverse the ovarian aging phenotype in old mice, rats and various disease models. The application provides a new effective target point, a treatment strategy and a product prototype with a transformation potential for intervention on ovarian aging and related diseases.

This utility model relates to the technical field of convenient testing kits for polycystic ovary syndrome (PCOS), and discloses a convenient testing kit for PCOS, including a sealed box and an installation mechanism. The sealed box has a connecting mechanism inside, which includes an outer frame with sliding grooves running through both sides. Through the installation mechanism, the test strip can be sealed with an aluminum foil bag, effectively isolating it from external contaminants and ensuring that it is not contaminated before use, thus ensuring accurate test results. In the placement slot of the testing kit, a flexible limiting component cooperates with a transparent adhesive film pasted on the surface to stabilize the aluminum foil bag and prevent it from colliding in the placement slot. In addition, the accessory slot is carefully designed to make full use of space for placing accessories such as droppers and instructions, making the accessories compact and orderly. This not only saves space but also makes it convenient for users to access the accessories. The required accessories can be easily found by opening the testing kit, greatly improving the convenience of the testing kit.

The present invention relates to benzothiophene derivatives modulators, processes for their preparation and use. In particular, the present invention relates to compounds of general formula (I), processes for their preparation, pharmaceutical compositions containing them and their use as modulators in the preparation of medicaments for the treatment of menopausal symptoms, polycystic ovary syndrome, uterine fibroids, schizophrenia, irritable bowel syndrome, vasomotor symptoms, breast cancer and related conditions, wherein the substituents of general formula (I) are as defined in the description.

The application belongs to the technical field of biological medicine, and specifically discloses application of 5-methylcytidine in preparation of a medicine for treating polycystic ovary syndrome, which aims to solve the problem that existing treatment methods are difficult to realize synchronous and coordinated improvement on key pathological phenotypes such as estrous cycle disorder, insulin resistance, and hyperandrogenemia, and the 5-methylcytidine involved is a pyrimidine nucleoside natural product, which is high in safety, low in toxic and side effects, and has unique curative effect in treatment of polycystic ovary syndrome.

The present invention provides a method of stratifying test subjects with Polycystic Ovary Syndrome (PCOS) into those that are expected to respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, those that are expected to respond to therapeutic treatment with an AKR1C3 inhibitor, and those that are expected to respond to therapeutic treatment with a 5alpha-reductase inhibitor, the method comprising: (a) providing a test sample from a test subject with PCOS; (b) determining the concentration / level in the test sample of at least one ovarian androgen steroid and / or a derivative thereof, and at least one adrenal steroid and / or derivative thereof; and (c) using the results from (b) to predict if the subject will respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, therapeutic treatment with an AKR1C3 inhibitor, or therapeutic treatment with a 5alpha-reductase inhibitor.

The application provides a health detection method and related equipment, the method comprises the following steps: acquiring physiological characteristics of a user; and performing polycystic ovary syndrome risk assessment according to the physiological characteristics of the user. According to the health detection method provided in the embodiments of the application, the user does not need to go to a hospital for polycystic ovary syndrome screening, and can perform polycystic ovary syndrome risk assessment by himself / herself, realizes real-time monitoring and management of the health status of the user, and reduces the risk of the user suffering from polycystic ovary syndrome.

The application discloses a combined biomarker combination and evaluation model for evaluating chronic low-grade inflammation of polycystic ovary syndrome, and belongs to the technical field of biomarkers. The combined biomarker combination comprises inflammation-related proteins and metabolites; the inflammation-related proteins comprise FURIN, CCL3, CCL8, CD38, NOS2, NOS3, IL18R1 and HGF; and the metabolites comprise lithocholic acid-3-O-glucuronide and taurine. The application provides a combined biomarker combination for diagnosing and evaluating the chronic inflammation state of polycystic ovary syndrome and an application method thereof. By jointly detecting specific inflammatory proteins and metabolites, the systemic chronic inflammation load of PCOS patients is quantitatively evaluated, and the combined biomarker combination has the beneficial effects of high stability, accurate discrimination, wide applicability and easy clinical transformation, and solves the problem that there is no objective evaluation method for the chronic inflammation state of PCOS.

The application provides application of animal Bifidobacterium lactis BGI-L99 in prevention and treatment of hormone imbalance and aging related diseases, and belongs to the technical field of biotechnology. The aforementioned animal Bifidobacterium lactis BGI-L99 is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on March 31, 2026, and the preservation number is GDMCC No. 68017. Products prepared from the animal Bifidobacterium lactis BGI-L99 in the examples of the application can effectively prevent and treat sex hormone imbalance related diseases and delay aging related degenerative diseases, including relieving polycystic ovary syndrome and osteoporosis, specifically including improving ovarian function, endocrine disorder, depression, metabolic disorder, inflammatory reaction, abnormal intestinal metabolic product, bone microstructure degradation, imbalance between bone formation and bone resorption and the like.

The present application relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating polycystic ovary syndrome, a preparation method and application thereof, which is prepared from raw medicinal materials in the following parts by weight: Yizhihu 10-20 parts, angelica 5-15 parts, polygonatum 8-16 parts, and gordon euryale 8-16 parts; the raw medicinal materials are mixed, then soaked in water, extracted by decocting after the soaking is completed, concentrated and dried to obtain the traditional Chinese medicine composition for treating polycystic ovary syndrome; the obtained traditional Chinese medicine composition can be further prepared into conventional oral preparations by conventional traditional Chinese medicine preparation methods. The present application innovatively proposes a treatment idea of "combination of opening and closing, and combination of dredging and tonifying". The so-called "opening" means soothing liver and relieving depression, regulating qi and menstruation to restore the dispersion of qi movement; the so-called "closing" means consolidating kidney essence and collecting the belt to prevent the dispersion of essence. The two methods are not contradictory, which can dredge and not hurt the normal, consolidate and not leave evil, and is especially suitable for PCOS patients with liver depression, blood deficiency, spleen and kidney deficiency, and essence instability.

This application relates to the field of focused ultrasound, and more particularly to a parameter localization method and kit for inhibiting PCOS-related epilepsy using focused ultrasound. The method includes: acquiring multiple preset power levels, each corresponding to different combinations of power and duty cycle; predicting the safe range of stimulation duration at different power levels based on prior experimental data and a biothermal model; setting several experimental parameter combinations with different preset doses based on the safe ranges; performing ultrasound stimulation on an experimental model based on the experimental parameter combinations and obtaining biological response results; fitting dose-response curves for each power level based on a preset dose-response relationship and the biological response results; determining the optimal dose range for each power level based on the dose-response curves, and evaluating the feasibility of the optimal dose range to determine the optimal parameter combination for focused ultrasound. This method efficiently determines a relatively accurate and effective range of ultrasound parameters while maintaining simple experimental operation, short cycle time, and low cost, providing support for personalized medicine.

This invention discloses sTREM1, a biomarker for assisting in the diagnosis of early spontaneous abortion, and its application, belonging to the field of biomedical technology. This invention is the first to discover a significant correlation between serum sTREM1 levels and early spontaneous abortion. In the early spontaneous abortion group and the 5-8 week gestation group, sTREM1 levels were significantly higher than those in the continued pregnancy group. Women experiencing early spontaneous abortion exhibit a unique dynamic pattern of progressively increasing sTREM1 levels, while those in the continued pregnancy show a slight decreasing trend. This invention further constructs a joint predictive model incorporating serum sTREM1 levels at 5-8 weeks of gestation, age ≥35 years, and polycystic ovary syndrome (PCOS), achieving an AUC as high as 0.823, demonstrating good discriminative and generalization abilities. Furthermore, decision curve analysis confirms that within the 10%-40% threshold probability range, the model's net benefit is superior to extreme treatment strategies. This invention is of great significance in the field of early spontaneous abortion risk prediction.

The application provides a construction method and application of a polycystic ovary syndrome animal model; through a way of intragastric administration, the mouse intestinal tract is transplanted with fusobacterium nucleatum, and through a certain frequency, the fusobacterium nucleatum can be stably planted, and a stable polycystic ovary syndrome symptom is successfully generated; the sex hormone level of the mouse is significantly different from the PCOS characteristic, is shown as the increase of the LH level, the LH / FSH ratio and the T level, and multiple vesicle structures are seen in the ovary, and no mature follicle and corpus luteum are seen, so that the typical symptom of the polycystic ovary syndrome is met, and a new model selection is provided for screening of a treatment drug or experimental research of the polycystic ovary syndrome.

The application provides a preparation method of a traditional Chinese medicine composition for treating polycystic ovary syndrome of spleen deficiency and phlegm dampness type. The application is based on Linggui Zhugan Decoction, and through long-term screening of effective substances and active ingredients, each medicinal material is extracted, separated and purified in a modern scientific way, and the extract is screened in combination with pharmacology and efficacy to form a new prescription, so that a new prescription with clear material basis and more accurate and significant curative effect is obtained. Through pharmacodynamic comparative study, it is determined that the effect of the traditional Chinese medicine composition provided by the application is obviously better than that of the control group. The traditional Chinese medicine composition can achieve the purposes of tonifying the kidney and invigorating the spleen, and resolving phlegm and dampness, can obviously regulate the endocrine and metabolic levels of PCOS patients of spleen deficiency and phlegm dampness type, and significantly improve the clinical symptoms. Further, the traditional Chinese medicine composition degrades fat through multiple pathways and multiple targets, promotes the recovery of ovarian function, promotes the growth and development of follicles, induces ovulation and the like, and has a significant effect in treating polycystic ovary syndrome of spleen deficiency and phlegm dampness type.

This invention discloses a formula for nourishing the kidneys, clearing heat, promoting diuresis, and resolving blood stasis, and its application. The formula comprises the following ingredients in parts by weight: Anemarrhena asphodeloides 7-13 parts, Rehmannia glutinosa 7-13 parts, Trionyx sinensis 12-18 parts, Dianthus superbus 7-13 parts, Dendrobium nobile 7-13 parts, Prunus persica 7-13 parts, Trichosanthes kirilowii 9-15 parts, Coptis chinensis 2-7 parts, Phellodendron chinense 7-13 parts, Cinnamomum cassia 2-7 parts, and Plantago asiatica 7-13 parts. This formula, provided by this invention, not only treats polycystic ovary syndrome but also significantly improves quality of life and has a role in preventing and treating depression. The present invention discloses a kidney-nourishing, heat-clearing, dampness-dispelling, and blood stasis-resolving formula and its application. The formula comprises the following raw materials by weight: 7-13 parts of Anemarrhena asphodeloides, 7-13 parts of Rehmannia glutinosa, 12-18 parts of turtle shell, 7-13 parts of Desmodium styracifolium, 7-13 parts of Dendrobium, 7-13 parts of peach kernel, 9-15 parts of Trichosanthes seed, 2-7 parts of Coptis chinensis, 7-13 parts of Phellodendron amurense, 2-7 parts of cinnamon twig, and 7-13 parts of Plantago major. The kidney-nourishing, heat-clearing, dampness-dispelling, and blood stasis-resolving formula provided by this invention is capable of significantly improving the quality of life and preventing depression while treating polycystic ovary syndrome.

A traditional Chinese medicine composition for nourishing kidney, clearing heat, removing dampness and removing blood stasis, an extract, a pharmaceutical preparation, a preparation method and an application thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: Anemarrhena asphodeloides 7-13 parts, Rehmannia glutinosa 7-13 parts, Trionyx sinensis 12-18 parts, Viola mandshurica 7-13 parts, Dendrobium 7-13 parts, Semen Pruni 7-13 parts, Semen Cucurbitae 9-15 parts, Coptis deltoidea 2-7 parts, Phellodendron amurense 7-13 parts, Cinnamomum cassia 2-7 parts, Plantago asiatica 7-13 parts, and Glycyrrhiza uralensis 2-12 parts. The traditional Chinese medicine composition can treat polycystic ovary syndrome, and can also significantly improve the quality of life and has the effect of preventing and treating depression.

This invention discloses a live birth prediction system for polycystic ovary syndrome (PCOS) patients after ovulation induction-guided intercourse. The system includes: a data acquisition module for acquiring basic data of PCOS patients; a preliminary screening module for calculating preliminary live birth rate predictors using a univariate Cox regression model based on the basic data; a final screening module for calculating final live birth rate predictors using a multivariate Cox regression model based on the preliminary live birth rate predictors; a live birth rate model construction module for constructing a live birth rate prediction model from the final live birth rate predictors; and a nomogram plotting module for plotting a live birth rate prediction nomogram based on the live birth rate prediction model to predict the live birth rate after ovulation induction-guided intercourse in PCOS patients. The system of this invention can accurately and effectively predict the live birth rate after ovulation induction-guided intercourse in PCOS patients.

Disclosed are compositions and methods including Anti-Müllerian Hormone (AMH) receptor binding peptides. The AMH receptor binding peptides can be used, for example, to modify the activity of the AMH receptor. For example, the AMH receptor binding peptides can activate the AMH receptor, such as the AMH receptor 2, thereby mimicking the function of AMH. In other examples, the AMH receptor binding peptides function as AMH receptor antagonists, thereby interfering with the function of endogenous AMH. By modifying the activity of the AMH receptor, the peptides have multiple applications, including for example modification of treatment of precocious puberty in females, delay of natural menopause, preservation of ovarian follicular reserve, contraception, fertility preservation after ovarian cortex transplant, treatment of endometriosis, treatment of cancer and / or cancer prevention, and treatment of polycystic ovary syndrome (PCOS).

The invention is in the field of biomedicine; and relates to Lacticaseibacillus paracasei subsp. tolerans, and a specific bacterial strain or a variant thereof, and their use in the treatment of insulin resistance syndrome, polycystic ovary syndrome, insulin resistance related infertility, gestational diabetes, obesity, and proinflammatory conditions. The invention also relates to a biologically pure culture, or the composition, or the pharmaceutical product, or the pharmaceutical composition, or the nutraceutical composition, or the food supplement, the feed, or the nutritional product comprising the specific bacterial strain or variant thereof, and a therapeutic method comprising administering the specific bacterial strain, or the biologically pure culture, or the composition, or the pharmaceutical product, or the pharmaceutical composition, or the nutraceutical composition, or the food supplement, the feed, or the nutritional product comprising the bacterial strain or a variant thereof.